Biotech's stock offering to fund work on stem cell product

08/15/2013 | San Diego Union-Tribune · Xconomy

Fate Therapeutics could secure as much as $69 million from an initial public offering, according to an SEC filing. The San Diego-based firm plans to use the money to further develop ProHema, its umbilical cord blood-based product designed to enhance the success of hematopoietic stem cell transplants, and other preclinical-stage products.

View Full Article in:

San Diego Union-Tribune · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA